(2015). Macrophages are critical effectors of antibody therapies for cancer. mAbs: Vol. 7, No. 2, pp. 303-310.
Via Krishan Maggon
Get Started for FREE
Sign up with Facebook Sign up with X
I don't have a Facebook or a X account
Your new post is loading...
Your new post is loading...
Krishan Maggon 's curator insight,
August 16, 2014 8:09 AM
open access
Addressing Dendritic Cells for Anticancer Immunity August 15, 2014 | Lutz Nuhn, PhD | Institute of Organic Chemistry, Johannes Gutenberg-University, Duesbergweg 10-14, D-55099 Mainz (Germany) | doi 10.14229/jadc.2014.8.15.002 Received August 5, 2014 | Accepted August 11, 2014 | Published online August 15, 2014
Keywords:
|
Krishan Maggon 's curator insight,
January 16, 2015 3:40 AM
Immunotherapy drugs are costly and are priced at more than $150000 per patient per year. |
pages 303-310
Publishing models and article dates explainedReceived: 4 Jan 2015Accepted: 15 Jan 2015Accepted author version posted online: 10 Feb 2015Article Views: 321pages 303-310
Publishing models and article dates explainedReceived: 4 Jan 2015Accepted: 15 Jan 2015Accepted author version posted online: 10 Feb 2015Article Views: 321